Tamsulosin - Key patent, SPC, and data exclusivity expiry (7 country coverage)

Tamsulosin - Key patent, SPC, and data exclusivity expiry (7 country coverage)

Pipeline Selector Core

Pipeline Selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 7 countries (44 country coverage also available), regulatory issues and key players.

This Pipeline Selector report covers Tamsulosin
Tamsulosin indications: Benign prostatic hyperplasia; Urinary disorders
Tamsulosin innovator: Boehringer Ingelheim (Flomax); Yamanouchi (Flomax); CSL (Flomax)

Examples of information found in this online report include:

• Includes key patent publications for 7 countries (see list below)
• Contains SPC protection for every EU state plus patent term extensions in other countries
• Data exclusivity calculated on a country by country basis
• Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
• DMF & Paragraph IV filings
• Litigation alerts
• Marketing authorisation holders in selected territories
• Patent risk analysis via graphical display of data from patent filings
• Hyper-linking to crucial patent documents and national registries enabling data verification

The 'Key Patent Indicator' enables easy identification of key patent, SPC and data protection expiry information covering 7 countries, including extension details (SPC and national law)(also available with 44 country coverage):

Pipeline Selector 7 Country Coverage:

Other key information contained in the report:

• Summary of dosage forms, strengths, indications and active ingredient forms of the brand product in major countriest**.
• News articles
• Litigation alerts
• Marketing authorisation holders for Great Britain, the United States, Canada and Australia enable you to see who is active in the market.
• US Drug Master Files, providing valuable information to help source active ingredients and keep an eye on competitors.
• Paragraph IV filing; details of US ANDAs filed with a Paragraph IV certification allow easy determination of who the first movers are for a particular generic product in the US.
• 'Patent Risk Analysis' section containing three graphical displays of data drawn from known patent filings to provide valuable competitor insight and development information***.

*Key Patent Indicator

The 'Key Patent Indicator' section is intended only to provide an indication of the Key Patents pertaining to a generic drug, and is not based on a comprehensive patent search (a comprehensive patent search can be found in the corresponding Pipeline Developer report).

**General Drug Information

Information contained in 'General Indications' and 'Brand Product Attributes' is based on products containing the active pharmaceutical ingredient, which are currently registered in Australia, UK and the USA. Indications are summarised where appropriate and may vary between individual countries.

***Patent Risk Analysis

The three graphical analyses are based on data contained in our Pipeline Developer comprehensive patent search, and thus are subject to its scope and limitations. These graphics are intended to provide only a summary of the patent filings; specific details of the filings should be investigated through the use of the Pipeline Developer reports.

Contents

• Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 7 countries (44 country coverage also available), regulatory issues and key players.
  • Includes key patent publications for 7 countries
  • Contains SPC protection for every EU state plus patent term extensions in other countries
  • Data exclusivity calculated on a country by country basis
  • Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
  • DMF & Paragraph IV filings
  • Litigation alerts
  • Marketing authorisation holders in selected territories
  • Patent risk analysis via graphical display of data from patent filings
  • Hyper-linking to crucial patent documents and national registries enabling data verification

Related products